

Clinicians and allied healthcare professionals seeking to further their HHT knowledge can now receive FREE continuing education credits through the HHT Continuing Education Program.

EARN FREE EDUCATION CREDITS* AT ANY TIME

- 1. Create an account on the HHT Continuing Education Hub at https://curehht.myabsorb.com
- 2. Enroll in and complete a course.
- Receive your certificate!

SCHEDULE A LIVE ON-DEMAND PRESENTATION FOR YOUR INSTITUTION

Ensure that providers at your institution have the most up-to-date information on HHT. Request live HHT Continuing Education at your clinic or institution, or incorporate these in your next conference or Grand Rounds!



*Credits available through this program include AMA PRA Category 1 Credit(s)™, ANCC contact hour(s), and IPCE credit(s).

HHT CME TOPICS: diagnosis, genetic testing, screening, evaluation, pediatrics, and management of the numerous manifestations of HHT, such as epistaxis, iron deficiency, anemia, pulmonary AVMs, brain AVMs, and liver VMs.

If you have any questions about the HHT Continuing Education Program, please email cme@curehht.org.



The HHT Continuing Education Program is accredited through Washington University School of Medicine in St Louis, which is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The HHT Continuing Education Program is fully supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$5,862,638 with 0 percentage financed with nongovernmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS or the U.S. Government.

An HHT Diagnosis Can Save a Life!



STATISTICS

- 25 years* the average time from first symptomatic visit to a physician until diagnosis
- 9 of 10 people with HHT are undiagnosed
- Lung and brain hemorrhage, stroke, brain abscess and death are preventable complications of AVMs if diagnosis and screening occur early
- **50% of HHT patients** suffer from anemia and iron deficiency which causes symptoms such as fatigue and migraines
- 1.4 million people worldwide have HHT
- Sudden death or disability occurs in 20% of undiagnosed children and adults

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu, is an autosomal dominant genetic disorder characterized by vascular malformations in multiple organs.

Patients can experience severe bleeding and anemia. Other complications include ischemic stroke, cerebral and pulmonary hemorrhage, pulmonary hypertension, and high-output cardiac failure, leading to significant morbidity and mortality. HHT is often misdiagnosed, and its symptoms are mistaken for other conditions. Men, women, and children of all ethnicities and races are equally affected.

Nosebleeds are a symptom in over 90% of people affected by HHT. Asking about family history and checking for the presence of telangiectases in anyone with chronic nosebleeds could help to diagnose an entire family.

Healthcare providers have the opportunity to recognize HHT in their patients and direct them to the care they need.

Cure HHT (HHT Foundation International, Inc.) is a 501(c)(3) organization whose mission is to find a cure for HHT while saving the lives and improving the well-being of individuals and families affected by HHT. We are the only organization in the world funding global advancements in awareness, research and treatments for HHT.

Scan the QR code to learn more about HHT and earn free continuing education credits.



^{*}Donaldson, JW. 2015. Complications and mortality in hereditary hemorrhagic telangiectasia: A population based study. Neurology. 84(18):1886-93